Top

Critical Care

Published in:

Open Access 01-12-2007 | Research

A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care

Authors: Christopher J Longo, Daren K Heyland, Harold N Fisher, Robert A Fowler, Claudio M Martin, Andrew G Day

Published in: Critical Care | Issue 6/2007

Abstract

Introduction

Recombinant human activated protein C (APC) therapy has been shown to reduce short-term mortality in patients with severe sepsis. However, survivors of sepsis may have long-term complications affecting health-related quality of life (HRQoL) and resource utilization. The objective of this study was to evaluate prospectively the effect of APC on long-term HRQoL and resource utilization compared with a nonrandomized control group that received standard care.

Methods

This was an observational cohort study at nine Canadian intensive care units. Patients with severe sepsis who survived to 28 days were recruited. Patients who received APC formed the treatment group and those that did not formed the standard care group. Patients who did not receive APC because of central nervous system bleeding risk were excluded from the standard care group. HRQoL (determined using the 36-item Short Form) and resource use were recorded at 28 days, and 3, 5 and 7 months.

Results

One hundred patients were enrolled (64 in the standard care group and 36 in the APC group), with 70 patients completing all follow-up visits. Over the 6 months of follow up, APC-treated patients exhibited statistically significantly better scores for the physical component score (P = 0.04) and trends toward improvements in physical functioning (P = 0.12), role physical (P = 0.10) and bodily pain (P = 0.14) as compared with standard care patients. Shorter hospital length of stay was observed for the APC group (36 days versus 48 days; P = 0.05).

Conclusion

These findings challenge earlier assumptions suggesting equivalent HRQoL and resource use in APC-treated and standard care patients who survive severe sepsis.

Available only for authorised users

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002CrossRef

Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Régnier B, French ICU Group for Severe Sepsis: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicentre prospective study in intensive care units. JAMA 1995, 274: 968-974. 10.1001/jama.274.12.968CrossRefPubMed

Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, Montani C, Magni E, The Italian SEPSIS Study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 1995, (Suppl 2):S244-S249. 10.1007/BF01740762

Pittet D, Rangel-Frausto S, Li N, Tarara D, Costigan M, Rempe L, Jebson P, Wenzel RP: Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 1995, 21: 302-309. 10.1007/BF01705408CrossRefPubMed

Ernst FR, Malatestinic W, Linde-Zwirble WT: Clinical and financial impact of severe sepsis. Am J Health Syst Pharm 2006, 63: 575-581. 10.2146/ajhp050214CrossRefPubMed

Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA: Long-term health related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2001, 28: 3599-3605. 10.1097/00003246-200011000-00006CrossRef

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed

Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR, PROWESS Investigators: The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004, 32: 2199-2206. 10.1097/01.CCM.0000114816.62331.08CrossRefPubMed

Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C: An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347: 993-1000. 10.1056/NEJMsa020969CrossRefPubMed

10.

Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B, PROWESS Investigators: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003, 31: 1-11. 10.1097/00003246-200301000-00001CrossRefPubMed

11.

Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM: Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003, 18: 181-191. 10.1016/j.jcrc.2003.08.009CrossRefPubMed

12.

Quartin AA, Schein RM, Kett DH, Peduzzi PN, for the Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group: Magnitude and duration of the effect of sepsis on survival. JAMA 1997, 277: 1058-1063. 10.1001/jama.277.13.1058CrossRefPubMed

13.

Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G III, Bernard GR, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003, 31: 834-840. 10.1097/01.CCM.0000051515.56179.E1CrossRefPubMed

14.

Lizana FG, Bota DP, De Cubber M, Vincent JL: Long-term outcome in ICU patients: What about quality of life? Intensive Care Med 2003, 29: 1286-1293. 10.1007/s00134-003-1875-zCrossRef

15.

Rogers J, Ridley S, Chrispin P, Scotton H, Lloyd D: Reliability of the next of kin's estimates of critically ill patient's quality of life. Anaesthesia 1997, 52: 1137-1143. 10.1111/j.1365-2044.1997.240-az0374.xCrossRefPubMed

16.

Groll DL, To T, Bombardier C, Wright JG: The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 2005, 58: 595-602. 10.1016/j.jclinepi.2004.10.018CrossRefPubMed

17.

Ware JE: The SF-36 health survey. In Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd edition. Edited by: Spilker B. Philadelphia, PA; Lippincott-Raven Publishers; 1996:337-345.

18.

Ware JE: SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.

19.

Ware JE, Kosinski M, Keller SD: SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, New England Medical Center; 1994.

20.

Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C, Joseph L, Brown JP, Murray TM, Adachi JD, et al.: Canadian normative data for the SF 36 health survey. CMAJ 2000, 163: 265-271.PubMedCentralPubMed

21.

Essink-Bot ML, Krabbe PF, Bonsel GJ, Aaronson NK: An empirical comparison of four generic health status measures. Med Care 1997, 35: 522-537. 10.1097/00005650-199705000-00008CrossRefPubMed

22.

Beaton DE, Hogg-Johnson S, Bombardier C: Evaluating changes in health status: Reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997, 50: 79-93. 10.1016/S0895-4356(96)00296-XCrossRefPubMed

23.

Ware JE: SF-36 health survey update. Spine 2000, 25: 3130-3139. 10.1097/00007632-200012150-00008CrossRefPubMed

24.

SAS Institute Inc: The MIXED Procedure. In SAS/STAT User's Guide, version 8. Cary, NC: SAS Institute Inc; 1999:2083-2226.

25.

Nichols MB, Sengupta N, Globe DR: Evaluating quality-adjusted life years: Estimation of the Health Utility Index (HUI2) from the SF-36. Med Decis Making 2001, 21: 105-112. 10.1177/02729890122062352CrossRef

26.

Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE: Predicting quality of well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997, 17: 1-9. 10.1177/0272989X9701700101CrossRefPubMed

27.

Havranek EP, McGovern KM, Weinberger J, Brocato A, Lowes BD, Abraham WT: Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. J Card Fail 1999, 5: 85-91. 10.1016/S1071-9164(99)90030-1CrossRefPubMed

28.

Heyland DK, Groll D, Caeser M: Survivors of acute respiratory distress syndrome: Relationship between pulmonary dysfunction and long-term health-related quality of life. Crit Care Med 2005, 33: 1549-1556. 10.1097/01.CCM.0000168609.98847.50CrossRefPubMed

29.

Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G: Long-term mortality and medical care costs in patients with severe sepsis. Crit Care Med 2003, 31: 2316-2323. 10.1097/01.CCM.0000085178.80226.0BCrossRefPubMed

30.

Alexander SL, Ernst FR: Use of drotrecogin alfa (activated) in older patients with severe sepsis. Pharmacotherapy 2006, 26: 533-538. 10.1592/phco.26.4.533CrossRefPubMed

31.

Iapichino G, Morabito A, Mistraletti G, Ferla L, Radrizzani D, Miranda DR: Determinants of post-intensive care mortality in high-level treated critically ill patients. Intensive Care Med 2003, 29: 1751-1756. 10.1007/s00134-003-1915-8CrossRefPubMed

Title: A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care
Authors: Christopher J Longo
Daren K Heyland
Harold N Fisher
Robert A Fowler
Claudio M Martin
Andrew G Day
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Critical Care / Issue 6/2007
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc6195

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2007

Discordance between microvascular permeability and leukocyte dynamics in septic inducible nitric oxide synthase deficient mice

Clinical review: Treatment of new-onset atrial fibrillation in medical intensive care patients: a clinical framework

Positive end-expiratory pressure in acute respiratory distress syndrome: should the 'open lung strategy' be replaced by a 'protective lung strategy'?

Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review

Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study

The impact of critical care outreach: is there one?